Subscribe Now Subscribe Today
Abstract
Fulltext PDF
References
Research Article
 

Effects of Tamoxifen and Glucose on Breast Cancer T47D Cells



Shamileh Fouladdel , Bagher Larijani and Ebrahim Azizi
 
ABSTRACT

Due to controversial reports on the relationship between diabetes and cancer, we decided to look at the effects of Tamoxifen (TAM) in the presence and absence of high glucose concentrations on proliferation of human breast cancer T47D cells and its Tamoxifen resistant subline (TAMR-6 cells). Both cell types were separately grown in 24-well culture plates for up to 4 weeks in the RPMI1640 culture medium containing TAM, different concentrations of glucose, combination of TAM and glucose and control (RPMI). Trypan blue dye exclusion method was used to evaluate the in vitro cytotoxicity of test compounds. Data indicated a time and dose dependent antiproliferative effect of glucose on T47D cells at studied concentrations. Results also showed that the cytotoxicity of glucose was significantly greater on parent T47D than TAMR-6 cells (p<0.01). A significant synergistic effect was also observed between TAM and glucose on both cell types (p<0.01). In conclusion, present results indicate that high glucose concentrations similar to diabetic conditions exert antiproliferative effects in breast cancer T47D cells.

Services
Related Articles in ASCI
Similar Articles in this Journal
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

Shamileh Fouladdel , Bagher Larijani and Ebrahim Azizi , 2006. Effects of Tamoxifen and Glucose on Breast Cancer T47D Cells . Journal of Biological Sciences, 6: 178-181.

DOI: 10.3923/jbs.2006.178.181

URL: https://scialert.net/abstract/?doi=jbs.2006.178.181

REFERENCES
Braun, M., 2002. Has tamoxifen had its time. Breast Cancer Res., 4: 213-217.
Direct Link  |  

Brown, P.H. and S.M. Lippman, 2000. Chemoprevention of breast cancer. Breast Cancer Res. Treatment, 62: 1-17.
CrossRef  |  Direct Link  |  

Chan, S., 2002. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin. Oncol., 29: 129-133.
Direct Link  |  

Chew, H.K., 2002. Medical management of breast cancer today and tomorrow. Cancer Biother Radiopharm, 17: 137-149.
CrossRef  |  

Clemons, M., S. Danson and A. Howell, 2002. Tamoxifen (Nolvadex) a review. Cancer Treat Rev., 28: 165-180.
PubMed  |  

Favoni, R.E. and A. Cupis, 1998. Steroidal and nonsteroidal oestrogen antagonists in breast cancer basic and clinical appraisal. Trends Pharmacol. Sci., 19: 406-415.
PubMed  |  

Fouladdel, S., Z. Motahari and E. Azizi, 2005. Expression of cyclin D1 in tamoxifen resistant subline of human breast cancer T47D cells. Int. J. Cancer Res., 1: 16-20.
CrossRef  |  Direct Link  |  

Freedman, A.N., B.I. Graubard, S.R. Rao, W. McCaskill-Stevens, R. Ballard-Barbash and M.H. Gail, 2003. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl. Cancer Inst., 95: 526-532.
PubMed  |  

Gajdos, C. and V.C. Jordan, 2002. Selective estrogen receptor modulators as a new therapeutic drug group concept to reality in a decade. Clin. Breast Cancer, 2: 272-281.
PubMed  |  

Hamlton, A. and M. Piccart, 1999. The third generation non steroidal aromatase inhibitors a review of their clinical benefits in the second line hormonal treatment of advanced breast cancer. Ann. Oncol., 10: 377-384.
Direct Link  |  

Johnston, S.R., 1997. Acquired tamoxifen resistance in human breast cancer potential mechanisms and clinical implications. Anticancer Drugs, 8: 911-930.
PubMed  |  

Jordan, C., 2002. Historical perspective on hormonal therapy of advanced breast cancer. Clin. Ther., 24: 3-16.
CrossRef  |  

Jordan, V.C., 1998. Antiestrogenic action of raloxifene and tamoxifen today and tomorrow. J. Natl. Cancer Inst., 90: 967-971.

Katzenellenbogen, B.S., 1996. Estrogen receptors bioactivities and interactions with cell signaling pathways. Biol. Reprod, 54: 287-293.
Direct Link  |  

Katzenellenbogen, B.S., M.M. Montano, K. Ekena, M.E. Herman, E.M. McInerney and L. William, 1997. McGuire Memorial Lecture antiestrogens mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat, 44: 23-38.

Lee, E.K., W.T. Regenold and P. Shapiro, 2002. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal regulated kinases. Anticancer Drugs, 13: 859-868.
Direct Link  |  

Levenson, A.S. and V.C. Jordan, 1999. Selective oestrogen receptor modulation molecular pharmacology for the millennium. Eur. J. Cancer, 35: 1628-1639.
Direct Link  |  

Lindley, C., 2002. Development in breast cancer therapy. J. Am. Pharm. Assoc., 42: 30-31.

Mink, P.J., E. Shahar, W.D. Rosamond, A.J. Alberg and A.R. Folsom, 2002. Serum insulin and glucose levels and breast cancer incidence the atherosclerosis risk in communities study. Am. J. Epidemiol., 156: 349-352.
Direct Link  |  

Okumura, M., M. Yamamoto, H. Sakuma, T. Kojima and K. Yasuda et al., 2002. Leptin and high glucose stimulate cell proliferation in MCF 7 human breast cancer cells reciprocal involvement of PKC and PPAR expression. Biochim. Biophys. Acta, 1592: 107-116.
PubMed  |  

Spyratos, F., P.M. Martin, K. Hacene, S. Romain and M. Brunet et al., 1992. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J. Natl. Cancer Inst., 84: 1266-1272.
PubMed  |  

Swain, S.M., M.E. Lippman, E.F. Egan, J.C. Drake, S.M. Steinberg and C.J. Allegra, 1989. Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7: 890-899.
PubMed  |  

Talamini, R., S. Franceschi, A. Favero, E. Negri, F. Parazzin and C.L. Vechia, 1997. Selected medical conditions and risk of breast cancer. Br. J. Cancer, 75: 1699-1703.
Direct Link  |  

Vechia, C.L., E. Negri, S. Franceschi, B.D Avanzo and P. Boyle, 1994. A case control study of diabetes mellitus and cancer risk. Br. J. Cancer, 70: 950-953.
PubMed  |  

Weiderpass, E., G. Gridley, I. Persson, O. Nyren, A. Ekbom and H.O. Adami, 1997. Risk of endometrial and breast cancer in patients with diabetes mellitus. Intl. J. Cancer, 71: 360-363.
PubMed  |  

Yamamoto, M., N.A. Patel, J. Taggart, R. Shidher and D.R. Cooper, 1999. A shift from normal to high glucose levels stimulates cell proliferation in drug sensitive MCF 7 human breast cancer cells but not in multidrug resistant MCF 7 ADR cells which overproduce PKC. Intl. J. Cancer, 83: 98-106.
Direct Link  |  

©  2019 Science Alert. All Rights Reserved
Fulltext PDF References Abstract